Biohaven Ltd. BHVN
15.20 USD -0.41 (-2.63%)
Nov 4, 2026, 2:00 PM EST
15.12 Day range 16.15
7.79 52-week range 16.95
- YTD
- +34.63%
- 1 year
- +8.96%
News
benzinga.com Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21 Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $19 to $21.
benzinga.com Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32 Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
benzinga.com Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate Biohaven (NYSE:BHVN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 50.34 percent increase over losses of $(1.47) per…
prnewswire.com Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global…
zacks.com Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the…
benzinga.com Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026 Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado.…
prnewswire.com Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into…
benzinga.com RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22 RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Sector Perform and raises the price target from $19 to $22.
barrons.com Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market…
benzinga.com Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Healthcare Services Group jumped 8.2% on an earnings beat. Biohaven led gainers, surging 30.5% after FDA news.
benzinga.com Biohaven Rebounds With FDA Review Date for Rare Disease Drug Biohaven Ltd. (NYSE:BHVN) stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 million after an update on the spinocerebellar ataxia (SCA) program.
benzinga.com Biohaven Rebounds With FDA Review Date for Rare Disease Drug FDA accepts Biohaven's Vyglxia NDA resubmission for SCA with a Q1 2027 goal date, planning an advisory committee review.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to…
benzinga.com Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement Biohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
benzinga.com Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
gurufocus.com Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phas
benzinga.com Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' Disease Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain…
prnewswire.com Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain…
gurufocus.com Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORT- benzinga.com Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer…
prnewswire.com Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer…
benzinga.com Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
benzinga.com Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
prnewswire.com Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK,…
barrons.com Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
benzinga.com HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
benzinga.com FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining…
benzinga.com FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
reuters.com US FDA pauses new enrollment in Biohaven's epilepsy drug trials Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down…
benzinga.com Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026 In June 2026, we announced that enrollment in BHV7000-303 was complete. Dosing continues and topline data readout remains on timeline for the second half of 2026. As part of the nonclinical…
benzinga.com RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19 RBC Capital analyst Leonid Timashev downgrades Biohaven (NYSE:BHVN) from Outperform to Sector Perform and lowers the price target from $23 to $19.
defenseworld.net BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVN BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE: BHVN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
fool.com Why Biohaven Stock Was Rocking the Market This Week Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.
seekingalpha.com Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves'…
seekingalpha.com Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash…
zacks.com BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
benzinga.com Why Is Biohaven Stock Soaring Wednesday? Biohaven Ltd. (NYSE:BHVN) scored two major wins this week. The company signed a lucrative licensing agreement with SK Biopharmaceuticals Co. Ltd. and secured a legal victory alongside Yale University…
benzinga.com Why Is Biohaven Stock Soaring Wednesday? Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
benzinga.com Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares rise 3.6% in pre-market trading.- benzinga.com Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on…
- benzinga.com Biohaven And Yale Win $4M Judgment Against Avilar And RA Capital Over Willful Misappropriation Of Yale Trade Secret Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment…
- benzinga.com Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19 Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.
- benzinga.com RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23 RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.
- benzinga.com Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate Biohaven (NYSE:BHVN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.73) by 6.85 percent. This is a 52.15 percent increase over losses of $(1.63) per…
- benzinga.com Biohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately…
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.